Menu
Back to Journals » OncoTargets and Therapy » Volume 12
Original Research
The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 8,110 | Dovepress* | 6,658+ | 1,018 | 7,676 | |
| PubMed Central* | 1,452 | 321 | 1,773 | ||
| Totals | 8,110 | 1,339 | 9,449 | ||
| *Since 8 July 2019 | |||||
View citations on PubMed Central and Google Scholar